Pacira BioSciences
PCRX
248 hedge funds and large institutions have $2.56B invested in Pacira BioSciences in 2020 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 88 increasing their positions, 72 reducing their positions, and 29 closing their positions.
83% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 29
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
62% more capital invested
Capital invested by funds: $1.58B → $2.56B (+$979M)
22% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 72
10% more funds holding
Funds holding: 226 → 248 (+22)
3.73% more ownership
Funds ownership: 111.93% → 115.66% (+3.7%)
35% less call options, than puts
Call options by funds: $6.23M | Put options by funds: $9.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$16M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.7M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$15.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 5 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$20.2M |
| 2 |
PC
Paulson & Co
New York
|
-$17.8M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
-$8.95M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$8M |
| 5 |
JG
Jefferies Group
New York
|
-$7.87M |
PCRX Hedge Fund Activity: Q2 2020 in Review
248 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2020, worth a combined $2.56B — up 62% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new PCRX positions and 29 closed out — a net gain of 24 holders — while 88 added to existing stakes and 72 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $16M. The largest seller was HealthCor Management, cutting an estimated $20.2M.
- 248 institutional investors held Pacira BioSciences (PCRX) as of Q2 2020, up from 226 in Q1 2020.
- Funds reported $2.56B of Pacira BioSciences stock for Q2 2020, up 62% quarter-over-quarter.
- 53 funds opened new Pacira BioSciences positions in Q2 2020 and 29 closed out, a net change of +24 holders.
- The largest Pacira BioSciences buyer in Q2 2020 was Renaissance Technologies, an estimated $16M added.
- The largest Pacira BioSciences seller in Q2 2020 was HealthCor Management, an estimated $20.2M sold.
Based on aggregated 13F filings for Q2 2020.